We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pathogen Reduction Evaluated in Treated Whole Blood

By LabMedica International staff writers
Posted on 21 Feb 2012
The survival of a parasite that can be transmitted by blood transfusion has been ascertained in whole blood treated with a commercial system. More...


The system which uses riboflavin (RB) and ultraviolet (UV) light to inactivate pathogens was used to reduce the levels of infectious Trypanosoma cruzi, the causative agent of Chagas disease in whole blood.

At the American Red Cross (Rockville, MD, USA), scientists inoculated with 4, 40, 400, and 4,000 trypomastigotes/mL into units of whole blood. The blood was transferred to Mirasol illumination bags, with the addition of 35 mL of 500 µmol/L RB solution, and the bag illumination of with UV light. The units were illuminated with 60, 80, and 110 joules/mL of red blood cells, with sample removal after delivery of each dose. Samples were collected pre- and post-illumination and cultured for the hemoflagellates

All preillumination samples exhibited T. cruzi growth in hemoculture, while postillumination samples from units containing 4 and 40 trypomastigotes/mL showed no signs of viable parasites after 16 weeks of culture. In contrast, at both 400 and 4,000 parasites/mL, two of the three units were positive for viable parasites. The total log reduction observed for T. cruzi was 3.5 log or greater, but less than 4.5 log. This level of reduction is likely to be orders of magnitude higher than what would be expected in a tainted blood donation.

The data from the study suggests that the Mirasol System (CaridianBCT; Lakewood, CO, USA) is able to inactivate clinically relevant amounts of T. cruzi in whole blood and it could be a viable alternative to a serologic screening assay. Additionally, this approach would avoid the need for multiple individual screening tests for other agents in a wide spectrum of marginal risks. Considering the challenges associated with T. cruzi testing, the Mirasol System could represent a useful tool in the quest for blood safety, indicating that the system could be effective at preventing transfusion of the causative agent of Chagas disease.

It has been shown that two decades after immigration, 33/52 (63%) of selected blood donors had polymerase chain reaction evidence of parasitemia and three also had culture-confirmed infection. This affirmation that bloodstream parasites are detectable and potentially transmissible, decades after immigration strengthens the rationale for donor screening or whole blood treatment. The study was published in the February 2012 edition of the journal Transfusion.

Related Links:
American Red Cross
CaridianBCT


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.